nodes	percent_of_prediction	percent_of_DWPC	metapath
Solifenacin—Vision blurred—Cisplatin—testicular cancer	0.0028	0.0028	CcSEcCtD
Solifenacin—Asthenia—Vinblastine—testicular cancer	0.0028	0.0028	CcSEcCtD
Solifenacin—Infection—Ifosfamide—testicular cancer	0.0028	0.0028	CcSEcCtD
Solifenacin—Nervous system disorder—Ifosfamide—testicular cancer	0.00276	0.00276	CcSEcCtD
Solifenacin—Skin disorder—Ifosfamide—testicular cancer	0.00274	0.00274	CcSEcCtD
Solifenacin—Feeling abnormal—Bleomycin—testicular cancer	0.00272	0.00272	CcSEcCtD
Solifenacin—Vomiting—Chlorambucil—testicular cancer	0.00271	0.00271	CcSEcCtD
Solifenacin—Dermatitis exfoliative—Epirubicin—testicular cancer	0.00269	0.00269	CcSEcCtD
Solifenacin—Decreased appetite—Dactinomycin—testicular cancer	0.00267	0.00267	CcSEcCtD
Solifenacin—Dysgeusia—Etoposide—testicular cancer	0.00267	0.00267	CcSEcCtD
Solifenacin—Renal impairment—Epirubicin—testicular cancer	0.00267	0.00267	CcSEcCtD
Solifenacin—Fatigue—Dactinomycin—testicular cancer	0.00265	0.00265	CcSEcCtD
Solifenacin—Urticaria—Bleomycin—testicular cancer	0.00262	0.00262	CcSEcCtD
Solifenacin—Dizziness—Vinblastine—testicular cancer	0.00258	0.00258	CcSEcCtD
Solifenacin—Feeling abnormal—Dactinomycin—testicular cancer	0.00253	0.00253	CcSEcCtD
Solifenacin—Nausea—Chlorambucil—testicular cancer	0.00253	0.00253	CcSEcCtD
Solifenacin—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—testicular cancer	0.00252	0.00252	CcSEcCtD
Solifenacin—Gastrointestinal pain—Dactinomycin—testicular cancer	0.00251	0.00251	CcSEcCtD
Solifenacin—Somnolence—Ifosfamide—testicular cancer	0.0025	0.0025	CcSEcCtD
Solifenacin—Liver function test abnormal—Methotrexate—testicular cancer	0.0025	0.0025	CcSEcCtD
Solifenacin—Dermatitis exfoliative—Doxorubicin—testicular cancer	0.00249	0.00249	CcSEcCtD
Solifenacin—Vomiting—Vinblastine—testicular cancer	0.00248	0.00248	CcSEcCtD
Solifenacin—Renal impairment—Doxorubicin—testicular cancer	0.00247	0.00247	CcSEcCtD
Solifenacin—Decreased appetite—Ifosfamide—testicular cancer	0.00245	0.00245	CcSEcCtD
Solifenacin—Headache—Vinblastine—testicular cancer	0.00244	0.00244	CcSEcCtD
Solifenacin—Gastrointestinal disorder—Ifosfamide—testicular cancer	0.00243	0.00243	CcSEcCtD
Solifenacin—Abdominal pain—Dactinomycin—testicular cancer	0.00243	0.00243	CcSEcCtD
Solifenacin—Fatigue—Ifosfamide—testicular cancer	0.00243	0.00243	CcSEcCtD
Solifenacin—Anaphylactic shock—Cisplatin—testicular cancer	0.00243	0.00243	CcSEcCtD
Solifenacin—Hypersensitivity—Bleomycin—testicular cancer	0.00243	0.00243	CcSEcCtD
Solifenacin—Infection—Cisplatin—testicular cancer	0.00241	0.00241	CcSEcCtD
Solifenacin—Constipation—Ifosfamide—testicular cancer	0.00241	0.00241	CcSEcCtD
Solifenacin—Nervous system disorder—Cisplatin—testicular cancer	0.00238	0.00238	CcSEcCtD
Solifenacin—Cough—Etoposide—testicular cancer	0.00238	0.00238	CcSEcCtD
Solifenacin—Tachycardia—Cisplatin—testicular cancer	0.00237	0.00237	CcSEcCtD
Solifenacin—Asthenia—Bleomycin—testicular cancer	0.00236	0.00236	CcSEcCtD
Solifenacin—Skin disorder—Cisplatin—testicular cancer	0.00236	0.00236	CcSEcCtD
Solifenacin—Hypertension—Etoposide—testicular cancer	0.00235	0.00235	CcSEcCtD
Solifenacin—Liver function test abnormal—Epirubicin—testicular cancer	0.00234	0.00234	CcSEcCtD
Solifenacin—Pruritus—Bleomycin—testicular cancer	0.00233	0.00233	CcSEcCtD
Solifenacin—Dry skin—Epirubicin—testicular cancer	0.00233	0.00233	CcSEcCtD
Solifenacin—Feeling abnormal—Ifosfamide—testicular cancer	0.00232	0.00232	CcSEcCtD
Solifenacin—Nausea—Vinblastine—testicular cancer	0.00232	0.00232	CcSEcCtD
Solifenacin—Abdominal pain upper—Epirubicin—testicular cancer	0.00232	0.00232	CcSEcCtD
Solifenacin—Unspecified disorder of skin and subcutaneous tissue—Etoposide—testicular cancer	0.0023	0.0023	CcSEcCtD
Solifenacin—Gastrointestinal pain—Ifosfamide—testicular cancer	0.0023	0.0023	CcSEcCtD
Solifenacin—Hypersensitivity—Dactinomycin—testicular cancer	0.00226	0.00226	CcSEcCtD
Solifenacin—Confusional state—Etoposide—testicular cancer	0.00224	0.00224	CcSEcCtD
Solifenacin—Muscular weakness—Epirubicin—testicular cancer	0.00224	0.00224	CcSEcCtD
Solifenacin—Urticaria—Ifosfamide—testicular cancer	0.00224	0.00224	CcSEcCtD
Solifenacin—Abdominal pain—Ifosfamide—testicular cancer	0.00223	0.00223	CcSEcCtD
Solifenacin—Anaphylactic shock—Etoposide—testicular cancer	0.00222	0.00222	CcSEcCtD
Solifenacin—Infection—Etoposide—testicular cancer	0.00221	0.00221	CcSEcCtD
Solifenacin—Asthenia—Dactinomycin—testicular cancer	0.00221	0.00221	CcSEcCtD
Solifenacin—Influenza—Epirubicin—testicular cancer	0.00219	0.00219	CcSEcCtD
Solifenacin—Dysuria—Methotrexate—testicular cancer	0.00219	0.00219	CcSEcCtD
Solifenacin—Tachycardia—Etoposide—testicular cancer	0.00217	0.00217	CcSEcCtD
Solifenacin—Liver function test abnormal—Doxorubicin—testicular cancer	0.00217	0.00217	CcSEcCtD
Solifenacin—Skin disorder—Etoposide—testicular cancer	0.00216	0.00216	CcSEcCtD
Solifenacin—Dry skin—Doxorubicin—testicular cancer	0.00215	0.00215	CcSEcCtD
Solifenacin—Abdominal pain upper—Doxorubicin—testicular cancer	0.00214	0.00214	CcSEcCtD
Solifenacin—Decreased appetite—Cisplatin—testicular cancer	0.00211	0.00211	CcSEcCtD
Solifenacin—Gastrointestinal disorder—Cisplatin—testicular cancer	0.0021	0.0021	CcSEcCtD
Solifenacin—Vomiting—Bleomycin—testicular cancer	0.0021	0.0021	CcSEcCtD
Solifenacin—Infestation NOS—Methotrexate—testicular cancer	0.00209	0.00209	CcSEcCtD
Solifenacin—Infestation—Methotrexate—testicular cancer	0.00209	0.00209	CcSEcCtD
Solifenacin—Depression—Methotrexate—testicular cancer	0.00208	0.00208	CcSEcCtD
Solifenacin—Rash—Bleomycin—testicular cancer	0.00208	0.00208	CcSEcCtD
Solifenacin—Dermatitis—Bleomycin—testicular cancer	0.00208	0.00208	CcSEcCtD
Solifenacin—Hypersensitivity—Ifosfamide—testicular cancer	0.00208	0.00208	CcSEcCtD
Solifenacin—Muscular weakness—Doxorubicin—testicular cancer	0.00207	0.00207	CcSEcCtD
Solifenacin—Renal failure—Methotrexate—testicular cancer	0.00205	0.00205	CcSEcCtD
Solifenacin—Dysuria—Epirubicin—testicular cancer	0.00205	0.00205	CcSEcCtD
Solifenacin—Influenza—Doxorubicin—testicular cancer	0.00203	0.00203	CcSEcCtD
Solifenacin—Asthenia—Ifosfamide—testicular cancer	0.00202	0.00202	CcSEcCtD
Solifenacin—Feeling abnormal—Cisplatin—testicular cancer	0.002	0.002	CcSEcCtD
Solifenacin—Pruritus—Ifosfamide—testicular cancer	0.00199	0.00199	CcSEcCtD
Solifenacin—Somnolence—Etoposide—testicular cancer	0.00198	0.00198	CcSEcCtD
Solifenacin—Hepatobiliary disease—Methotrexate—testicular cancer	0.00198	0.00198	CcSEcCtD
Solifenacin—Nausea—Bleomycin—testicular cancer	0.00196	0.00196	CcSEcCtD
Solifenacin—Infestation NOS—Epirubicin—testicular cancer	0.00196	0.00196	CcSEcCtD
Solifenacin—Infestation—Epirubicin—testicular cancer	0.00196	0.00196	CcSEcCtD
Solifenacin—Vomiting—Dactinomycin—testicular cancer	0.00195	0.00195	CcSEcCtD
Solifenacin—Rash—Dactinomycin—testicular cancer	0.00194	0.00194	CcSEcCtD
Solifenacin—Decreased appetite—Etoposide—testicular cancer	0.00193	0.00193	CcSEcCtD
Solifenacin—Renal failure—Epirubicin—testicular cancer	0.00192	0.00192	CcSEcCtD
Solifenacin—Gastrointestinal disorder—Etoposide—testicular cancer	0.00192	0.00192	CcSEcCtD
Solifenacin—Fatigue—Etoposide—testicular cancer	0.00192	0.00192	CcSEcCtD
Solifenacin—Constipation—Etoposide—testicular cancer	0.0019	0.0019	CcSEcCtD
Solifenacin—Urinary tract infection—Epirubicin—testicular cancer	0.0019	0.0019	CcSEcCtD
Solifenacin—Dysuria—Doxorubicin—testicular cancer	0.0019	0.0019	CcSEcCtD
Solifenacin—Dizziness—Ifosfamide—testicular cancer	0.00186	0.00186	CcSEcCtD
Solifenacin—Pharyngitis—Methotrexate—testicular cancer	0.00186	0.00186	CcSEcCtD
Solifenacin—Urinary tract disorder—Methotrexate—testicular cancer	0.00185	0.00185	CcSEcCtD
Solifenacin—Hepatobiliary disease—Epirubicin—testicular cancer	0.00185	0.00185	CcSEcCtD
Solifenacin—Urethral disorder—Methotrexate—testicular cancer	0.00184	0.00184	CcSEcCtD
Solifenacin—Feeling abnormal—Etoposide—testicular cancer	0.00183	0.00183	CcSEcCtD
Solifenacin—Nausea—Dactinomycin—testicular cancer	0.00183	0.00183	CcSEcCtD
Solifenacin—Gastrointestinal pain—Etoposide—testicular cancer	0.00182	0.00182	CcSEcCtD
Solifenacin—Infestation NOS—Doxorubicin—testicular cancer	0.00181	0.00181	CcSEcCtD
Solifenacin—Infestation—Doxorubicin—testicular cancer	0.00181	0.00181	CcSEcCtD
Solifenacin—Vomiting—Ifosfamide—testicular cancer	0.00179	0.00179	CcSEcCtD
Solifenacin—Hypersensitivity—Cisplatin—testicular cancer	0.00179	0.00179	CcSEcCtD
Solifenacin—Renal failure—Doxorubicin—testicular cancer	0.00178	0.00178	CcSEcCtD
Solifenacin—Rash—Ifosfamide—testicular cancer	0.00178	0.00178	CcSEcCtD
Solifenacin—Dermatitis—Ifosfamide—testicular cancer	0.00177	0.00177	CcSEcCtD
Solifenacin—Erythema multiforme—Methotrexate—testicular cancer	0.00177	0.00177	CcSEcCtD
Solifenacin—Urticaria—Etoposide—testicular cancer	0.00177	0.00177	CcSEcCtD
Solifenacin—Abdominal pain—Etoposide—testicular cancer	0.00176	0.00176	CcSEcCtD
Solifenacin—Urinary tract infection—Doxorubicin—testicular cancer	0.00176	0.00176	CcSEcCtD
Solifenacin—Eye disorder—Methotrexate—testicular cancer	0.00175	0.00175	CcSEcCtD
Solifenacin—Asthenia—Cisplatin—testicular cancer	0.00174	0.00174	CcSEcCtD
Solifenacin—Pharyngitis—Epirubicin—testicular cancer	0.00174	0.00174	CcSEcCtD
Solifenacin—Cardiac disorder—Methotrexate—testicular cancer	0.00174	0.00174	CcSEcCtD
Solifenacin—Urinary tract disorder—Epirubicin—testicular cancer	0.00173	0.00173	CcSEcCtD
Solifenacin—Oedema peripheral—Epirubicin—testicular cancer	0.00173	0.00173	CcSEcCtD
Solifenacin—Connective tissue disorder—Epirubicin—testicular cancer	0.00172	0.00172	CcSEcCtD
Solifenacin—Urethral disorder—Epirubicin—testicular cancer	0.00172	0.00172	CcSEcCtD
Solifenacin—Hepatobiliary disease—Doxorubicin—testicular cancer	0.00171	0.00171	CcSEcCtD
Solifenacin—Angiopathy—Methotrexate—testicular cancer	0.0017	0.0017	CcSEcCtD
Solifenacin—Immune system disorder—Methotrexate—testicular cancer	0.00169	0.00169	CcSEcCtD
Solifenacin—Mediastinal disorder—Methotrexate—testicular cancer	0.00169	0.00169	CcSEcCtD
Solifenacin—Nausea—Ifosfamide—testicular cancer	0.00167	0.00167	CcSEcCtD
Solifenacin—Erythema multiforme—Epirubicin—testicular cancer	0.00166	0.00166	CcSEcCtD
Solifenacin—Mental disorder—Methotrexate—testicular cancer	0.00164	0.00164	CcSEcCtD
Solifenacin—Eye disorder—Epirubicin—testicular cancer	0.00164	0.00164	CcSEcCtD
Solifenacin—Hypersensitivity—Etoposide—testicular cancer	0.00164	0.00164	CcSEcCtD
Solifenacin—Malnutrition—Methotrexate—testicular cancer	0.00163	0.00163	CcSEcCtD
Solifenacin—Cardiac disorder—Epirubicin—testicular cancer	0.00163	0.00163	CcSEcCtD
Solifenacin—Pharyngitis—Doxorubicin—testicular cancer	0.00161	0.00161	CcSEcCtD
Solifenacin—Urinary tract disorder—Doxorubicin—testicular cancer	0.0016	0.0016	CcSEcCtD
Solifenacin—Oedema peripheral—Doxorubicin—testicular cancer	0.0016	0.0016	CcSEcCtD
Solifenacin—Dysgeusia—Methotrexate—testicular cancer	0.0016	0.0016	CcSEcCtD
Solifenacin—Asthenia—Etoposide—testicular cancer	0.0016	0.0016	CcSEcCtD
Solifenacin—Connective tissue disorder—Doxorubicin—testicular cancer	0.0016	0.0016	CcSEcCtD
Solifenacin—Angiopathy—Epirubicin—testicular cancer	0.00159	0.00159	CcSEcCtD
Solifenacin—Urethral disorder—Doxorubicin—testicular cancer	0.00159	0.00159	CcSEcCtD
Solifenacin—Immune system disorder—Epirubicin—testicular cancer	0.00159	0.00159	CcSEcCtD
Solifenacin—Mediastinal disorder—Epirubicin—testicular cancer	0.00158	0.00158	CcSEcCtD
Solifenacin—Pruritus—Etoposide—testicular cancer	0.00157	0.00157	CcSEcCtD
Solifenacin—Vomiting—Cisplatin—testicular cancer	0.00154	0.00154	CcSEcCtD
Solifenacin—Vision blurred—Methotrexate—testicular cancer	0.00154	0.00154	CcSEcCtD
Solifenacin—Mental disorder—Epirubicin—testicular cancer	0.00154	0.00154	CcSEcCtD
Solifenacin—Erythema multiforme—Doxorubicin—testicular cancer	0.00154	0.00154	CcSEcCtD
Solifenacin—Rash—Cisplatin—testicular cancer	0.00153	0.00153	CcSEcCtD
Solifenacin—Dermatitis—Cisplatin—testicular cancer	0.00153	0.00153	CcSEcCtD
Solifenacin—Malnutrition—Epirubicin—testicular cancer	0.00153	0.00153	CcSEcCtD
Solifenacin—Eye disorder—Doxorubicin—testicular cancer	0.00152	0.00152	CcSEcCtD
Solifenacin—Cardiac disorder—Doxorubicin—testicular cancer	0.00151	0.00151	CcSEcCtD
Solifenacin—Dysgeusia—Epirubicin—testicular cancer	0.0015	0.0015	CcSEcCtD
Solifenacin—Angiopathy—Doxorubicin—testicular cancer	0.00147	0.00147	CcSEcCtD
Solifenacin—Dizziness—Etoposide—testicular cancer	0.00147	0.00147	CcSEcCtD
Solifenacin—Immune system disorder—Doxorubicin—testicular cancer	0.00147	0.00147	CcSEcCtD
Solifenacin—Mediastinal disorder—Doxorubicin—testicular cancer	0.00146	0.00146	CcSEcCtD
Solifenacin—Nausea—Cisplatin—testicular cancer	0.00144	0.00144	CcSEcCtD
Solifenacin—Vision blurred—Epirubicin—testicular cancer	0.00144	0.00144	CcSEcCtD
Solifenacin—Cough—Methotrexate—testicular cancer	0.00142	0.00142	CcSEcCtD
Solifenacin—Mental disorder—Doxorubicin—testicular cancer	0.00142	0.00142	CcSEcCtD
Solifenacin—Vomiting—Etoposide—testicular cancer	0.00141	0.00141	CcSEcCtD
Solifenacin—Malnutrition—Doxorubicin—testicular cancer	0.00141	0.00141	CcSEcCtD
Solifenacin—Rash—Etoposide—testicular cancer	0.0014	0.0014	CcSEcCtD
Solifenacin—Dermatitis—Etoposide—testicular cancer	0.0014	0.0014	CcSEcCtD
Solifenacin—Headache—Etoposide—testicular cancer	0.00139	0.00139	CcSEcCtD
Solifenacin—Dysgeusia—Doxorubicin—testicular cancer	0.00138	0.00138	CcSEcCtD
Solifenacin—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—testicular cancer	0.00138	0.00138	CcSEcCtD
Solifenacin—Palpitations—Epirubicin—testicular cancer	0.00135	0.00135	CcSEcCtD
Solifenacin—Confusional state—Methotrexate—testicular cancer	0.00134	0.00134	CcSEcCtD
Solifenacin—Cough—Epirubicin—testicular cancer	0.00133	0.00133	CcSEcCtD
Solifenacin—Anaphylactic shock—Methotrexate—testicular cancer	0.00133	0.00133	CcSEcCtD
Solifenacin—Vision blurred—Doxorubicin—testicular cancer	0.00133	0.00133	CcSEcCtD
Solifenacin—Infection—Methotrexate—testicular cancer	0.00132	0.00132	CcSEcCtD
Solifenacin—Nausea—Etoposide—testicular cancer	0.00132	0.00132	CcSEcCtD
Solifenacin—Hypertension—Epirubicin—testicular cancer	0.00132	0.00132	CcSEcCtD
Solifenacin—Nervous system disorder—Methotrexate—testicular cancer	0.00131	0.00131	CcSEcCtD
Solifenacin—Skin disorder—Methotrexate—testicular cancer	0.00129	0.00129	CcSEcCtD
Solifenacin—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—testicular cancer	0.00129	0.00129	CcSEcCtD
Solifenacin—Dry mouth—Epirubicin—testicular cancer	0.00127	0.00127	CcSEcCtD
Solifenacin—Confusional state—Epirubicin—testicular cancer	0.00126	0.00126	CcSEcCtD
Solifenacin—Palpitations—Doxorubicin—testicular cancer	0.00125	0.00125	CcSEcCtD
Solifenacin—Anaphylactic shock—Epirubicin—testicular cancer	0.00125	0.00125	CcSEcCtD
Solifenacin—Infection—Epirubicin—testicular cancer	0.00124	0.00124	CcSEcCtD
Solifenacin—Cough—Doxorubicin—testicular cancer	0.00123	0.00123	CcSEcCtD
Solifenacin—Nervous system disorder—Epirubicin—testicular cancer	0.00122	0.00122	CcSEcCtD
Solifenacin—Hypertension—Doxorubicin—testicular cancer	0.00122	0.00122	CcSEcCtD
Solifenacin—Tachycardia—Epirubicin—testicular cancer	0.00122	0.00122	CcSEcCtD
Solifenacin—Skin disorder—Epirubicin—testicular cancer	0.00121	0.00121	CcSEcCtD
Solifenacin—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—testicular cancer	0.0012	0.0012	CcSEcCtD
Solifenacin—Somnolence—Methotrexate—testicular cancer	0.00118	0.00118	CcSEcCtD
Solifenacin—Dry mouth—Doxorubicin—testicular cancer	0.00118	0.00118	CcSEcCtD
Solifenacin—Dyspepsia—Methotrexate—testicular cancer	0.00117	0.00117	CcSEcCtD
Solifenacin—Confusional state—Doxorubicin—testicular cancer	0.00116	0.00116	CcSEcCtD
Solifenacin—Decreased appetite—Methotrexate—testicular cancer	0.00116	0.00116	CcSEcCtD
Solifenacin—Anaphylactic shock—Doxorubicin—testicular cancer	0.00115	0.00115	CcSEcCtD
Solifenacin—Gastrointestinal disorder—Methotrexate—testicular cancer	0.00115	0.00115	CcSEcCtD
Solifenacin—Fatigue—Methotrexate—testicular cancer	0.00115	0.00115	CcSEcCtD
Solifenacin—Infection—Doxorubicin—testicular cancer	0.00115	0.00115	CcSEcCtD
Solifenacin—Nervous system disorder—Doxorubicin—testicular cancer	0.00113	0.00113	CcSEcCtD
Solifenacin—Tachycardia—Doxorubicin—testicular cancer	0.00113	0.00113	CcSEcCtD
Solifenacin—Skin disorder—Doxorubicin—testicular cancer	0.00112	0.00112	CcSEcCtD
Solifenacin—Somnolence—Epirubicin—testicular cancer	0.00111	0.00111	CcSEcCtD
Solifenacin—Feeling abnormal—Methotrexate—testicular cancer	0.0011	0.0011	CcSEcCtD
Solifenacin—Dyspepsia—Epirubicin—testicular cancer	0.0011	0.0011	CcSEcCtD
Solifenacin—Gastrointestinal pain—Methotrexate—testicular cancer	0.00109	0.00109	CcSEcCtD
Solifenacin—Decreased appetite—Epirubicin—testicular cancer	0.00108	0.00108	CcSEcCtD
Solifenacin—Gastrointestinal disorder—Epirubicin—testicular cancer	0.00108	0.00108	CcSEcCtD
Solifenacin—Fatigue—Epirubicin—testicular cancer	0.00108	0.00108	CcSEcCtD
Solifenacin—Constipation—Epirubicin—testicular cancer	0.00107	0.00107	CcSEcCtD
Solifenacin—Urticaria—Methotrexate—testicular cancer	0.00106	0.00106	CcSEcCtD
Solifenacin—Abdominal pain—Methotrexate—testicular cancer	0.00105	0.00105	CcSEcCtD
Solifenacin—Feeling abnormal—Epirubicin—testicular cancer	0.00103	0.00103	CcSEcCtD
Solifenacin—Somnolence—Doxorubicin—testicular cancer	0.00103	0.00103	CcSEcCtD
Solifenacin—Gastrointestinal pain—Epirubicin—testicular cancer	0.00102	0.00102	CcSEcCtD
Solifenacin—Dyspepsia—Doxorubicin—testicular cancer	0.00102	0.00102	CcSEcCtD
Solifenacin—Decreased appetite—Doxorubicin—testicular cancer	0.001	0.001	CcSEcCtD
Solifenacin—Gastrointestinal disorder—Doxorubicin—testicular cancer	0.000996	0.000996	CcSEcCtD
Solifenacin—Fatigue—Doxorubicin—testicular cancer	0.000995	0.000995	CcSEcCtD
Solifenacin—Urticaria—Epirubicin—testicular cancer	0.000991	0.000991	CcSEcCtD
Solifenacin—Constipation—Doxorubicin—testicular cancer	0.000987	0.000987	CcSEcCtD
Solifenacin—Abdominal pain—Epirubicin—testicular cancer	0.000986	0.000986	CcSEcCtD
Solifenacin—Hypersensitivity—Methotrexate—testicular cancer	0.000982	0.000982	CcSEcCtD
Solifenacin—Asthenia—Methotrexate—testicular cancer	0.000956	0.000956	CcSEcCtD
Solifenacin—Feeling abnormal—Doxorubicin—testicular cancer	0.000951	0.000951	CcSEcCtD
Solifenacin—Gastrointestinal pain—Doxorubicin—testicular cancer	0.000943	0.000943	CcSEcCtD
Solifenacin—Pruritus—Methotrexate—testicular cancer	0.000943	0.000943	CcSEcCtD
Solifenacin—Hypersensitivity—Epirubicin—testicular cancer	0.000919	0.000919	CcSEcCtD
Solifenacin—Urticaria—Doxorubicin—testicular cancer	0.000917	0.000917	CcSEcCtD
Solifenacin—Abdominal pain—Doxorubicin—testicular cancer	0.000912	0.000912	CcSEcCtD
Solifenacin—Asthenia—Epirubicin—testicular cancer	0.000895	0.000895	CcSEcCtD
Solifenacin—Pruritus—Epirubicin—testicular cancer	0.000882	0.000882	CcSEcCtD
Solifenacin—Dizziness—Methotrexate—testicular cancer	0.000881	0.000881	CcSEcCtD
Solifenacin—Hypersensitivity—Doxorubicin—testicular cancer	0.00085	0.00085	CcSEcCtD
Solifenacin—Vomiting—Methotrexate—testicular cancer	0.000847	0.000847	CcSEcCtD
Solifenacin—Rash—Methotrexate—testicular cancer	0.00084	0.00084	CcSEcCtD
Solifenacin—Dermatitis—Methotrexate—testicular cancer	0.000839	0.000839	CcSEcCtD
Solifenacin—Headache—Methotrexate—testicular cancer	0.000835	0.000835	CcSEcCtD
Solifenacin—Asthenia—Doxorubicin—testicular cancer	0.000828	0.000828	CcSEcCtD
Solifenacin—Dizziness—Epirubicin—testicular cancer	0.000825	0.000825	CcSEcCtD
Solifenacin—Pruritus—Doxorubicin—testicular cancer	0.000816	0.000816	CcSEcCtD
Solifenacin—Vomiting—Epirubicin—testicular cancer	0.000793	0.000793	CcSEcCtD
Solifenacin—Nausea—Methotrexate—testicular cancer	0.000791	0.000791	CcSEcCtD
Solifenacin—Rash—Epirubicin—testicular cancer	0.000786	0.000786	CcSEcCtD
Solifenacin—Dermatitis—Epirubicin—testicular cancer	0.000786	0.000786	CcSEcCtD
Solifenacin—Headache—Epirubicin—testicular cancer	0.000781	0.000781	CcSEcCtD
Solifenacin—Dizziness—Doxorubicin—testicular cancer	0.000763	0.000763	CcSEcCtD
Solifenacin—Nausea—Epirubicin—testicular cancer	0.000741	0.000741	CcSEcCtD
Solifenacin—Vomiting—Doxorubicin—testicular cancer	0.000734	0.000734	CcSEcCtD
Solifenacin—Rash—Doxorubicin—testicular cancer	0.000727	0.000727	CcSEcCtD
Solifenacin—Dermatitis—Doxorubicin—testicular cancer	0.000727	0.000727	CcSEcCtD
Solifenacin—Headache—Doxorubicin—testicular cancer	0.000723	0.000723	CcSEcCtD
Solifenacin—Nausea—Doxorubicin—testicular cancer	0.000685	0.000685	CcSEcCtD
